Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm open-label study of encorafenib + binimetinib with immunotherapy to overcome primary resistance in BRAF-mutant metastatic melanoma
MOH_2023-01-23_012300Phase 2Not yet recruiting
- Sponsor
- דוקטור רוני שפירא פרומר
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and pembrolizumab in melanoma, sponsored by דוקטור רוני שפירא פרומר. Primary endpoints: Immune response to treatment combinations and Response rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2023-01-23_012300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-23_012300.